Clinical Trial Update: Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Vebreltinib and Osimertinib in advanced non-small cell lung cancer with an EGFR L858R mutation; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Vebreltinib (vebreltinib)

Snippet

Sponsor: National Cancer Center, China | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING